Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
The response of dogs with insulinoma to surgical and medical management is variable, with the majority developing intractable hypoglycaemia. A long-acting somatostatin analogue, Octreotide (SMS 201-995; Sandostatin) has been useful in the management of hypoglycaemia in humans with insulinoma, and preliminary reports suggest a beneficial clinical response in dogs with insulinoma. The present study objectively evaluated Octreotide in the management of three dogs with immunohistochemically confirmed insulinoma. Octreotide had no benefit over placebo, and little effect on circulating glucose and insulin concentrations despite clearly detectable plasma concentrations of Octreotide. No clinical improvement was apparent in two dogs given Octreotide over a period of two and three weeks. These results contrast with the positive clinical responses noted previously and indicate that further placebo controlled, objective studies are necessary before clear statements on the treatment of insulinoma with Octreotide are made.
Simpson
K W
KW
Department of Small Animal Medicine and Surgery, Royal Veterinary College, Hatfield, Hertfordshire.
Stepien
R L
RL
Elwood
C M
CM
Boswood
A
A
Vaillant
C R
CR
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004341:Drug Evaluation; D005260:Female; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D007328:Insulin / Q000097:blood; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*
D001786:Blood Glucose; D007328:Insulin; D015282:Octreotide